A nonrandomized clinical trial called “Accelerating lung cancer diagnosis through liquid biopsy” (ACCELERATE) discovered that early liquid biopsies based on circulating tumor DNA (ctDNA) genotyping can significantly reduce the time to treatment for people with advanced non-small cell lung cancer (NSCLC). The study, published in JAMA Network Open, employed next-generation sequencing to detect ctDNA in blood plasma samples from 150 patients suspected of having advanced lung cancer. Plasma ctDNA testing prior to lung cancer diagnosis resulted in a shorter time to molecular results, more frequent identification of actionable targets, and a shorter time to treatment for all patients with nonsquamous NSCLC who took part in the trial. The ctDNA genotyping findings were usually available within a week, whereas standard tissue biopsy results took longer.

To know more: About the original article click here.